Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLBE | ISIN: SE0012675361 | Ticker-Symbol: 6IRA
Frankfurt
28.03.25
08:25 Uhr
0,634 Euro
-0,016
-2,46 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IRLAB THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
IRLAB THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur IRLAB THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrIRLAB Therapeutics: IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease637GOTHENBURG, SE / ACCESS Newswire / March 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, March 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that...
► Artikel lesen
DoIRLAB Therapeutics - Next steps laid out for IRL757186IRLAB has confirmed that clinical candidate IRL757, which has been designed to address apathy in patients with neurodegenerative conditions, will proceed to the next stages of clinical development....
► Artikel lesen
DoIRLAB Therapeutics: IRLAB to Initiate a Study of IRL757 in Parkinsons's Disease with Full Financial Backing from its Development Partner MSRD206ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY. GOTHENBURG, SE / ACCESS Newswire / March 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company...
► Artikel lesen
12.03.IRLAB (OMX: IRLAB-A) publishes preclinical mesdopetam data in journal259IRLAB Therapeutics has announced the publication of preclinical data on mesdopetam in the prestigious peer-reviewed journal, European Journal of Neuroscience. The research provided insights into the...
► Artikel lesen
12.03.IRLAB Therapeutics: IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience146GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and...
► Artikel lesen
11.03.IRLAB Therapeutics: IRLAB Participates in Stora Aktiedagarna169GOTHENBURG, SE / ACCESS Newswire / March 11, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease...
► Artikel lesen
05.03.IRLAB Therapeutics (OMX: IRLAB-A) misses primary endpoint with pirepemat241IRLAB Therapeutics has announced top-line results from the Phase IIb REACT-PD study evaluating its second most clinically advanced asset, pirepemat, as a potential treatment for falls related to Parkinson's...
► Artikel lesen
05.03.IRLAB Therapeutics: IRLAB Reports Topline Results from a Phase IIb Study of Pirepemat in Patients with Parkinson's Disease261GOTHENBURG, SE / ACCESS Newswire / March 5, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's disease...
► Artikel lesen
IRLAB THERAPEUTICS Aktie jetzt für 0€ handeln
27.02.IRLAB (OMX: IRLAB-A) publishes Phase IIb mesdopetam results in journal206IRLAB Therapeutics has announced that the results from its Phase IIb clinical trial, evaluating mesdopetam as a potential treatment to address levodopa induced dyskinesias, have been published in the...
► Artikel lesen
27.02.IRLAB Therapeutics: IRLAB Publishes Phase IIb Data on Mesdopetam in Movement Disorders Clinical Practice472GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
20.02.IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans305IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company...
► Artikel lesen
20.02.IRLAB Therapeutics: IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam251GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company...
► Artikel lesen
18.02.IRLAB Therapeutics - Financing improves operational flexibility216IRLAB Therapeutics has renegotiated its loan terms with Fenja Capital, allowing it to extend the duration of its SEK55m loan from 22 May 2025, potentially to 30 June 2026. The loan value may also be...
► Artikel lesen
18.02.IRLAB Therapeutics (STO: IRLAB-A) announces loan term extension and new shareholder loan263IRLAB has renegotiated its loan terms with FENJA Capital, allowing it to extend duration of the SEK55m loan from May 2025 to 31 December 2025 and potentially to 30 June 2026 (for an additional fee of...
► Artikel lesen
18.02.IRLAB Therapeutics: IRLAB Strengthens Its Value Creation Capabilities Through Extended And Expanded Debt Financing353GOTHENBURG, SWEDEN / ACCESS Newswire / February 17, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)/ IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments...
► Artikel lesen
12.02.IRLAB Therapeutics: IRLAB Publishes Full-Year Report for 2024262GOTHENBURG, SE / ACCESS Newswire / February 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 12, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
07.02.IRLAB Therapeutics: IRLAB: Invitation to the Year-End Report 2024 Presentation and Webcast239GOTHENBURG, SE / ACCESS Newswire / February 7, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 7, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering...
► Artikel lesen
03.02.IRLAB Therapeutics - Phase I data supports IRL757's development229IRLAB Therapeutics has reported positive top-line data from one of the two ongoing Phase I clinical trials evaluating its third clinical-stage asset, IRL757, as a potential treatment for apathy. This...
► Artikel lesen
31.01.IRLAB Therapeutics (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort265IRLAB Therapeutics has reported positive top-line data from one of two ongoing Phase I studies evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center...
► Artikel lesen
31.01.IRLAB (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort276IRLAB Therapeutics has reported positive topline data from one of two ongoing Phase I studies, evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center...
► Artikel lesen
Seite:  Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1